Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
2024年1月8日 - 9:00PM
Absci Corporation (Nasdaq: ABSI), a generative AI drug creation
company, today announced the company will be presenting positive
preclinical data for ABS-101, a potential best-in-class anti-TL1A
antibody program, this week at the 42nd Annual J.P. Morgan
Healthcare Conference.
Absci’s Integrated Drug Creation™ platform
designed over 50 antibody leads with subnanomolar affinity using
its de novo generative AI foundation model, enabling a diversity of
potential candidates. Absci has selected three potential candidates
for the ABS-101 program utilizing its AI lead optimization
capabilities.
In preclinical studies, ABS-101 potential
candidates exhibited properties consistent with a potentially
superior product profile by demonstrating equal or superior potency
data from multiple biophysical and cellular assays, in addition to
improved developability properties, as compared to estimated
performance of a putative clinical competitor molecule in later
stages of development. These attributes support the program’s
potential to create an efficacious candidate conducive to
subcutaneous dosing. Furthermore, in vitro and preliminary in vivo
PK studies confirm the potential for extended half-life, supporting
the objective for significantly improved dosing intervals.
These preclinical results demonstrate the
ability of Absci’s generative AI platform to rapidly and
efficiently create differentiated antibody drug candidates.
Supporting data for these assessments can be found in the
associated company presentation for the upcoming J.P. Morgan
Healthcare Conference, published on Absci’s investor relations
website.
Absci expects to initiate Investigational New
Drug application (IND) enabling studies for ABS-101 in February
2024, and submit an IND in the first quarter of 2025. Subject to
clearance of the IND, Absci expects to initiate Phase 1 studies for
this program shortly thereafter.
Absci management is scheduled to present these
data, and other corporate updates, on Thursday, January 11th at
10:30 a.m. Pacific Time (1:30 p.m. Eastern Time). Interested
parties may access a live and archived webcast of the presentation
on the company’s investor relations website at:
investors.absci.com.
About Absci
Absci is a generative AI drug creation company
that combines AI with scalable wet lab technologies to create
better biologics for patients, faster. Our Integrated Drug
Creation™ platform unlocks the potential to accelerate time to
clinic and increase the probability of success by simultaneously
optimizing multiple drug characteristics important to both
development and therapeutic benefit. With the data to train, the AI
to create, and the wet lab to validate, we can screen billions of
cells per week, allowing us to go from AI-designed antibodies to
wet lab-validated candidates in as little as six weeks. Our vision
is to deliver breakthrough therapeutics at the click of a button,
for everyone. Absci’s headquarters is in Vancouver, WA, with our AI
Research Lab in New York City and an Innovation Center in Zug,
Switzerland. Visit www.absci.com and follow us on LinkedIn
(@absci), X (Twitter) (@Abscibio), and YouTube.
Availability of Other Information about
AbsciInvestors and others should note that we routinely
communicate with investors and the public using our website
(www.absci.com) and our investor relations website
(investors.absci.com), including without limitation, through the
posting of investor presentations, SEC filings, press releases,
public conference calls and webcasts on these websites, as well as
on X (Twitter), LinkedIn and YouTube. The information that we post
on these websites and social media outlets could be deemed to be
material information. As a result, investors, the media, and others
interested in Absci are encouraged to review this information on a
regular basis. The contents of our website and social media
postings, or any other website that may be accessed from our
website or social media postings, shall not be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended.
Forward-Looking
StatementsCertain statements in this press release that
are not historical facts are considered forward-looking within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements containing the words “will,” “may,” “pursues,”
“anticipates,” “plans,” “believes,” “aims,” “potential,”
“forecast,” “estimates,” “extends,” “expects,” and “intends,” or
similar expressions. We intend these forward-looking statements,
including statements regarding timing of IND submission for ABS-101
and Phase 1 trials thereafter; the significance of preclinical
results for ABS-101, including in comparison to competitor
molecules; technology development efforts and the application of
those efforts, including acceleration of drug development
timelines, reducing the time and costs related to drug development,
advancements toward drug discovery and development activities, the
success of our partnerships and their ability to generate
scientific and technical insights for using AI drug creation to
accelerate the development of candidate therapies, developing a
diverse, high-value portfolio of novel drug treatments, and the
anticipated value to us under our partnership, to be covered by the
safe harbor provisions for forward-looking statements contained in
Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act, and we make this statement for purposes of complying
with those safe harbor provisions. These forward-looking statements
reflect our current views about our plans, intentions,
expectations, strategies, and prospects, which are based on the
information currently available to us and on assumptions we have
made. We can give no assurance that the plans, intentions,
expectations, or strategies will be attained or achieved, and
furthermore, actual results may differ materially from those
described in the forward-looking statements and will be affected by
a variety of risks and factors that are beyond our control,
including, without limitation, risks and uncertainties relating to
obtaining and maintaining necessary approvals from the FDA and
other regulatory authorities; replicating in clinical trials
positive results found in preclinical studies; our dependence on
third parties to support our internal development programs,
including for the manufacture and supply of preclinical and
clinical supplies of our product candidates or components thereof;
our ability to effectively collaborate on research, drug discovery
and development activities with our partners or potential partners;
our existing and potential partners’ ability and willingness to
pursue the development and commercialization of programs or product
candidates under the terms of our partnership agreements; and
overall market conditions and regulatory developments that may
affect our and our partners’ activities under these agreements,
along with those risks set forth in our most recent periodic report
filed with the U.S. Securities and Exchange Commission, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the U.S. Securities and
Exchange Commission. Except as required by law, we assume no
obligation to update publicly any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
Investor ContactAlex KhanVP,
Finance & Investor Relationsinvestors@absci.com
Media
Contactpress@absci.com
AbSci (NASDAQ:ABSI)
過去 株価チャート
から 4 2024 まで 5 2024
AbSci (NASDAQ:ABSI)
過去 株価チャート
から 5 2023 まで 5 2024